Remarkable Response to Rituximab in a 72-Year-Old Patient with Refractory Non-Hodgkin's Lymphoma and Marrow Aplasia

G. Egerer Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Hospitalstr. 3, 69115, Heidelberg, Germany

K. Sauerland Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Hospitalstr. 3, 69115, Heidelberg, Germany

A. D. Ho Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Hospitalstr. 3, 69115, Heidelberg, Germany

References

McLaughlin P., Grillo-López A., Czuczman M., et al. IDEC-C2B8 (rituximab): clinical activity in clinically chemoresistant (CCRD) low grade or follicular lymphoma (LG/F) and in patients (pts) relapsing after anthracycline therapy (ANTHRA-RX) or, ABMT. Proceedings of the American Society of Clinical Oncology 1997; 16: 16a
Google Scholar
Byrd J. C., Waselenko J. K., Maneatis T. J., et al. Ritximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance. Journal of Clinical Oncology 1999; 17: 791–795
PubMed Web of Science ®Google Scholar
Vose J. M., Link B. K., Grossbard M. L., Fisher R. I., Czuczman M. S., Grillo-López A., Oilman P., Lowe A., Kunkel L A. Phase II Study of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate-or high-grade non-Hodgkin's lymphoma (NHL). Blood 1999; 94, Abstract 388
Web of Science ®Google Scholar
Czuczman M., Grillo-López A. J., White C. A., et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Journal of Clinical Oncology 1999; 17: 268–276
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Remarkable Response to Rituximab in a 72-Year-Old Patient with Refractory Non-Hodgkin's Lymphoma and Marrow Aplasia

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Remarkable Response to Rituximab in a 72-Year-Old Patient with Refractory Non-Hodgkin's Lymphoma and Marrow Aplasia

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date